➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Baxter
McKinsey
Mallinckrodt
Johnson and Johnson

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

Patent: 5,385,825

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,385,825
Title: Composition for processing bodyfluids, method of processing bodyfluids and products made from bodyfluids
Abstract:Disclosed is a composition useful in the processing of blood and cerebrospinal fluid to help maintain sample integrity for analytical testing. The composition generally includes a first enzyme inhibitor selected from the group of enzyme inhibitors consisting of inhibitors which allow substantially the function of metalo-peptidase while inhibiting at least one enzyme selected from the group of enzymes consisting of endopeptidase, exopeptidase and sulfhydryl-mediated proteases, and inhibitors which substantially inhibit the function of metalo-peptidase, wherein where the first enzyme inhibitor inhibits metalo-peptidase, the assaying composition further comprises a second enzyme inhibitor suitable to inhibit at least one enzyme selected from the group of enzymes consisting of endopeptidase, exopeptidase, metalo-peptidase and sulfhydryl-mediated proteases. Further disclosed is an apparatus which includes a tube containing the inhibitors into which the bodyfluids are placed. In the method, blood or cerebrospinal fluid is contacted with the inhibitors prior to analytical testing. Also disclosed are products of the bodyfluids and inhibitors which are useful for analytical testing.
Inventor(s): Ezrailson; Edward G. (The Woodlands, TX)
Assignee: Emerald Biomedical Sciences, Inc. (The Woodlands, TX)
Application Number:08/094,512
Patent Claims:see list of patent claims

Details for Patent 5,385,825

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23 ⤷  Free Forever Trial Emerald Biomedical Sciences, Inc. (The Woodlands, TX) 2039-02-26 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23 ⤷  Free Forever Trial Emerald Biomedical Sciences, Inc. (The Woodlands, TX) 2039-02-26 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23 ⤷  Free Forever Trial Emerald Biomedical Sciences, Inc. (The Woodlands, TX) 2039-02-26 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23 ⤷  Free Forever Trial Emerald Biomedical Sciences, Inc. (The Woodlands, TX) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
AstraZeneca
McKesson
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.